Drug intelligence / Profile preview

SBX-2023

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

**SBX-2023** is a plant-based therapeutic candidate being developed by Stramsen Biotech for peripheral neuropathic disorders. The company identifies it as one of its plant-derived pharmaceutical pipeline assets, but has not publicly disclosed its molecular composition, biological target, mechanism of action, dosage form, route of administration, or clinical phase for this specific candidate.

Beyond the preview

Go deeper on SBX-2023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-2023.

Explore the full profile